Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease
| العنوان: | Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease |
|---|---|
| المؤلفون: | Patrick Sulzgruber, Andreas Hammer, Ronny Schweitzer, Christian Hengstenberg, Lorenz Koller, Alexander Niessner, Niema Kazem, Felix Hofer, Friedrich Jakse |
| المصدر: | Cardiovascular Drugs and Therapy. 35:1161-1170 |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Male, 0301 basic medicine, medicine.medical_specialty, Coronary Artery Disease, 030204 cardiovascular system & hematology, Glucagon-Like Peptide-1 Receptor, Body Mass Index, Coronary artery disease, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, medicine, Humans, Hypoglycemic Agents, Pharmacology (medical), In patient, Practice Patterns, Physicians', Medical prescription, Receptor, Sodium-Glucose Transporter 2 Inhibitors, Aged, Cardiovascular mortality, Pharmacology, business.industry, Hazard ratio, General Medicine, Middle Aged, medicine.disease, Glucagon-like peptide-1, Prescriptions, 030104 developmental biology, Diabetes Mellitus, Type 2, Sodium/Glucose Cotransporter 2, Female, Cardiology and Cardiovascular Medicine, business |
| الوصف: | To assess real-world data on the clinical implementation of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in cardiovascular patients and to investigate barriers to prescribe these agents. Patients presenting with coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) between 01/2014 and 04/2020 were included in the present analysis and followed prospectively. All first-time prescriptions of SGLT2i and GLP-1RA were identified. Among 1498 patients with CAD and T2DM, 17.6% of patients received an SGLT2i and 5.5% a GLP-1RA. The prescription of SGLT2i (+38.7%; p < 0.001) and GLP-1RA (+8%; p = 0.007) significantly increased during the observation period. Considering remuneration criteria for SGLT2i therapy, lowering the GFR cut-off to 30 ml/min/1.73 m2 would allow additional 26.6% of patients to qualify for an SGLT2i therapy. While SGLT2i therapy was inversely associated with CV mortality (adjusted hazard ratio of 0.18 [95% CI: 0.05–0.76]; p = 0.019), GLP-1RA therapy showed a trend for risk reduction. The present analysis revealed an infrequent prescription of SGLT2i and GLP-1RAs in patients with T2DM and CAD in clinical practice. Remuneration regulations that better reflect the inclusion criteria of the CV outcome trials would allow more patients at high risk to receive these CV protective drugs. Most importantly, while GLP-1RA therapy showed a trend for risk reduction of cardiovascular mortality, the use of SGLT2i had a strong inverse impact on cardiovascular mortality from a long-term perspective. |
| تدمد: | 1573-7241 0920-3206 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b19b3af03b1042614c2d0c22778928eaTest https://doi.org/10.1007/s10557-021-07160-8Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....b19b3af03b1042614c2d0c22778928ea |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15737241 09203206 |
|---|